+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
JENBURPH JENBURPH

Jenburkt Pharmaceuticals Share Price

₹925.60 +9.55 (1.04%)
29.93% Fall from 52W High

19 Oct, 2026 4:01 PM (IST)

Jenburkt Pharmaceuticals live price: ₹925.60. It opened at ₹921 vs previous close ₹916; intraday high/low: ₹926/₹910. The 50 & 200 DMA stand at ₹984.70/₹1,057.40.

Jenburkt Pharmaceuticals Performance

  • Today's Low
  • ₹910
  • Today's High
  • ₹926
  • 52 Week Low
  • ₹880
  • 52 Week High
  • ₹1,321
  • Open Price₹921
  • Previous Close₹916
  • Volume867
  • 50 DMA₹984.70
  • 100 DMA₹1,025.10
  • 200 DMA₹1,057.40

Jenburkt Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -5.36%
  • Over 3 Month -15.97%
  • Over 6 Month -9.75%
  • Over 1 Year -7.84%

Smart Investing Starts Here Start SIP with Jenburkt Pharmaceuticals for Steady Growth!

Invest Now

Jenburkt Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.4
  • PEG Ratio
  • 10.3
  • Market Cap Cr
  • 409
  • P/B Ratio
  • 2
  • Average True Range
  • 37.8
  • EPS
  • 74.4
  • Dividend Yield
  • 2.2
  • MACD Signal
  • -23.2
  • RSI
  • 41.58
  • MFI
  • 34.83

Latest Stock News Updates

Jenburkt Pharmaceuticals Ltd - 524731 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Counter Cyclical Investment Pvt Ltd

Jenburkt Pharmaceuticals Ltd - 524731 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.

Jenburkt Pharmaceuticals Ltd - 524731 - Intimation Regarding Admission Of Equity Shares Of The Company Under 'Permitted To Trade' Category On National Stock Exchange Of India Limited.

Intimation regarding admission of Equity shares of the Company under " Permitted to trade" category on National Stock Exchange of India Limited.

Jenburkt Pharmaceuticals Financials

Jenburkt Pharmaceuticals Technicals

EMA & SMA

Current Price
₹925.60
+ 9.55 (1.04%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹938.40
  • 50 Day
  • ₹984.70
  • 100 Day
  • ₹1,025.10
  • 200 Day
  • ₹1,057.40

Resistance and Support

920.47 Pivot Speed
  • R3 946.10
  • R2 935.90
  • R1 930.70
  • S1 915.30
  • S2 905.10
  • S3 899.90

Jenburkt Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-06 Quarterly Results
2026-05-05 Audited Results, Final Dividend & A.G.M.
2026-02-03 Quarterly Results
2025-10-28 Quarterly Results
2025-08-12 Quarterly Results
Date Purpose Remarks
2026-08-28 FINAL Rs.20.70 per share(207%)Final Dividend
2025-07-11 FINAL Rs.18.00 per share(180%)Final Dividend
View Jenburkt Pharmaceuticals Dividend History Arrow

Jenburkt Pharmaceuticals Shareholding Pattern

53.34%
46.62%
0.03%

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals is in the business of manufacturing, producing, developing and marketing a wide range of branded Pharmaceuticals and health care products. View More
  • NSE Symbol
  • JENBURPH
  • BSE Symbol
  • 524731
  • ISIN
  • INE354A01013

Similar Stocks to Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals FAQs

Jenburkt Pharmaceuticals share price is ₹925 As on 19 October, 2026 | 19:05

The Market Cap of Jenburkt Pharmaceuticals is ₹408.5 Cr As on 19 October, 2026 | 19:05

The P/E ratio of Jenburkt Pharmaceuticals is 12.4 As on 19 October, 2026 | 19:05

The PB ratio of Jenburkt Pharmaceuticals is 2 As on 19 October, 2026 | 19:05

The 52 week High & Low of Jenburkt Pharmaceuticals is ₹1321/₹880.1 respectively As on 19 October, 2026 | 19:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23